Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalfampridine in Primary Lateral Sclerosis
NCT02868567Phase 1Completed
- Sponsor
- Hospital for Special Surgery
- Start
- Mar 2016
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalfampridine in primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS), sponsored by Hospital for Special Surgery. Primary endpoint: Timed 25-Foot Walk at 18 weeks. Started Mar 2016; status: completed.
02
Drugs
dalfampridine
03
Conditions
primary lateral sclerosis (PLS)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02868567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02868567.